Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

被引：24
|
作者：
Faivre-Finn, C. [1 ,2 ]
Vicente, D. [3 ]
Kurata, T. [4 ]
Planchard, D. [5 ]
Paz-Ares, L. [6 ,7 ]
Vansteenkiste, J. F. [8 ]
Spigel, D. R. [9 ,10 ]
Garassino, M. C. [11 ]
Reck, M. [12 ]
Senan, S. [13 ]
Naidoo, J. [14 ,15 ,16 ]
Rimner, A. [16 ]
Wu, Y-L. [17 ,18 ]
Gray, J. E. [19 ]
Ozguroglu, M. [20 ]
Lee, K. H. [21 ]
Newton, M. [22 ]
Wang, L. [22 ]
Thiyagarajah, P. [23 ]
Antonia, S. J. [19 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Hosp Univ Virgen Macarena, Seville, Spain
[4] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[5] Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France
[6] Univ Complutense, Hosp Univ 12 Octubre, CiberOnc, Madrid, Spain
[7] CNIO, Madrid, Spain
[8] Univ Hosp KU Leuven, Dept Resp Oncol, Leuven, Belgium
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Tennessee Oncol, Nashville, TN USA
[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[12] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany
[13] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands
[14] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[15] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[16] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
[17] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Dept Pulm Oncol, Guangzhou, Peoples R China
[18] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[19] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[20] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey
[21] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[22] AstraZeneca, Gaithersburg, MD USA
[23] AstraZeneca, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA49
引用
收藏
页码：S1178 / S1179
页数：2
相关论文
共 50 条
  • [31] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
    Bischoff, Helge
    Garassino, Marina Chiara
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Cove-Smith, Laura
    Mansy, Talal
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    Reinmuth, Niels
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 160 - 161
  • [32] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
    Garassino, M. C.
    Mazieres, J.
    Reck, M.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L.
    Mansy, T.
    Cortinovis, D.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. Garcia
    Velarde, L. E. Chara
    Bernabe, R.
    Paz-Ares, L.
    Perez, I. Diaz
    Trunova, N.
    Foroutanpour, K.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S81 - S82
  • [33] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
    Filippi, A. R.
    Bar, J.
    Chouaid, C.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Garassino, M. C.
    Garrido, P.
    Haakensen, V. D.
    Kao, S.
    Markman, B.
    Mcdonald, F.
    Mornex, F.
    Moskovitz, M.
    Peters, S.
    Sibille, A.
    Siva, S.
    Heuvel, M. van den
    Vercauter, P.
    Anand, S.
    Chander, P.
    Licour, M.
    Lima, A. R. de
    Qiao, Y.
    Girard, N.
    ESMO OPEN, 2024, 9 (06)
  • [34] Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
    Brunsvig, Paal Fr.
    Kyte, Jon Amund
    Kersten, Christian
    Sundstrum, Stein
    Muller, Mona
    Nyakas, Marta
    Hansen, Gaute L.
    Gaudernack, Gustav
    Aamdal, Steinar
    CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6847 - 6857
  • [35] Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
    Faivre-Finn, Corinne
    Spigel, David R.
    Senan, Suresh
    Langer, Corey
    Perez, Bradford A.
    Ozguroglu, Mustafa
    Daniel, Davey
    Villegas, Augusto
    Vicente, David
    Hui, Rina
    Murakami, Shuji
    Paz-Ares, Luis
    Broadhurst, Helen
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott J.
    LUNG CANCER, 2021, 151 : 30 - 38
  • [36] PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
    Wu, Y-L.
    Wu, L.
    Bi, N.
    Cil, T.
    Ge, H.
    Zhu, Z.
    Wang, C-L.
    Zhang, W.
    Lv, D.
    Sun, J.
    Pan, Y.
    Krzakowski, M.
    Dikilitas, M.
    Sendur, M. A. N.
    Kim, Y-C.
    Yang, Y.
    Mao, R.
    Zhang, B.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1624 - S1624
  • [37] The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Kim, Y.
    Choi, Y-K
    Kwak, Y-K
    Lee, Y-H
    Kim, S-H
    Sung, S-Y
    Son, S-H
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S281 - S281
  • [38] PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
    McDonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Christoph, D.
    Haakensen, V. D.
    Agbarya, A.
    Van den Heuvel, M.
    Vercauter, P.
    Chouaid, C.
    Pichon, E.
    Siva, S.
    Steinbusch, L.
    Peretz, I.
    Solomon, B.
    Decoster, L.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S738 - S739
  • [39] Impact of chemoradiotherapy on the survival of patients with stage III NSCLC
    Basto, R.
    Correia Magalhaes, J.
    de Sousa, M. J. P.
    Monteiro, J. C.
    Domingues, I.
    Jesus, E.
    Sousa, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S743 - S743
  • [40] First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC
    Faehling, Martin
    Planchard, David
    Cho, Byoung Chul
    Gray, Jhanelle Elaine
    Paz-Ares, Luis G.
    Ozguroglu, Mustafa
    Villegas, Augusto E.
    Daniels, Davey B.
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Gu, Yu
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott Joseph
    de Wit, Maike
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
12345